论文部分内容阅读
目的评价低分子肝素钙联合长春西汀治疗进展型脑梗死的临床疗效及安全型。方法将59例进展型脑梗死患者随机分为两组,治疗组以低分子肝素钙5000U脐周皮下注射,每12h 1次,连用7d,长春西汀30mg加入生理盐水250ml中静脉点滴,每日1次,连用14d;对照组予常规治疗,疗程14d。观察治疗前后神经功能缺损评分并判定疗效,并检测血小板计数、凝血酶原时间、纤维蛋白原、肝肾功能。结果治疗后神经功能缺损改善治疗组优于对照组,临床显效亦优于对照组(P<0.05),两组治疗前后血小板计数、凝血酶原时间、纤维蛋白原等差异无统计学意义(P>0.05),两组均未发现脑出血情况。结论低分子肝素钙联合长春西汀治疗进展型脑梗死是安全有效的治疗方案。
Objective To evaluate the clinical efficacy and safety of low molecular weight heparin combined with vinpocetine in the treatment of advanced cerebral infarction. Methods Fifty-nine patients with progressive cerebral infarction were randomly divided into two groups. The treatment group was subcutaneously injected with low-molecular-weight heparin 5000U umbilical cord every 12 hours for 7 days. The vinpocetine 30 mg was given intravenously in 250 ml of normal saline. The daily 1 time, once every 14d; control group to conventional treatment, treatment 14d. The score of neurological impairment before and after treatment was observed and the curative effect was evaluated. The platelet count, prothrombin time, fibrinogen, liver and kidney function were also measured. Results After treatment, the improvement of neurological deficit in treatment group was better than that of control group, and the clinical effect was better than that of control group (P <0.05). There was no significant difference in platelet count, prothrombin time and fibrinogen between the two groups before and after treatment (P > 0.05). No cerebral hemorrhage was found in both groups. Conclusion Low molecular weight heparin combined with vinpocetine in the treatment of advanced cerebral infarction is a safe and effective treatment.